Human gastric cancer (GC) is a leading primary cause of cancer-associated deaths in both males and females worldwide. However, there are few effective diagnostic and therapeutic measures for GC patients due to the complicated underlying mechanisms of GC. Recently, increasing research has indicated that lncRNAs may play a critical role in the progression of GC.
Background
Gastric cancer (GC), characterized by high incidence and poor prognosis, is among the most common malignant tumors in males and females worldwide [1, 2] . According to the Lauren classification, GC can be divided into 2 different types: intestinal (characterized by dysplastic changes) and diffuse types [3] . It was reported that GC is the third leading cause of cancerrelated deaths in the males and the fifth most frequent cause in females [4] . According to the cancer statistics of the United State in 2016, it is estimated that more than 26 000 new GC cases and more than 10 000 deaths occurred [1] . Due to enormous progress in diagnostic and therapeutic options, the global incidence of GC is now slowly decreasing [5, 6] . However, the prognosis of GC is still extremely poor, especially in advanced GC patients. Due to the lack of effective biomarkers for use in diagnosis, most GC patients are diagnosed at advanced or metastatic stages [7, 8] . For these advanced or metastatic GC patients, the main therapeutic measure is chemotherapy, but it has very limited effects and poor prognosis [9] [10] [11] . Therefore, it is extremely urgent to determine the exact underlying molecular mechanisms of GC, and to find effective therapeutic targets for patients with GC.
Long non-coding RNAs (lncRNAs), which are more than 200 nucleotides in length and lack protein-coding capacity, are important members of the non-coding RNAs (ncRNAs) family. Although lncRNAs do not code for proteins, they can regulate gene expression by interaction with the corresponding gene at transcriptional and post-transcriptional levels. Emerging evidence shows that lncRNAs are involved in the pathogenesis of various tumors, such as colorectal cancer [12] , hepatocellular cancer [13] , and lung cancer [14] . Recently, several reports have indicated that many lncRNAs are associated with the progression of GC, including lncRNA H19 [15] , lncRNA HOTAIR [16] , and lncRNA LINC00152 [17] .
In the present study, we first measured the expression levels of 6 lncRNAs: AI769947, AK054978, DB077273, BG981369, AK054588, and AF131784. Our results showed that BG981369 expression was significantly downregulated in GC tissues compared to normal tissues. We then performed qRT-PCR, MTT, apoptosis analysis, wound-healing assay, and Transwell assay in a BG981369-overexpressed cell model and a BG981369 knockdown cell model, showing that knockdown of BG981369 promotes cell proliferation, migration, and invasion, and inhibits cell apoptosis in GC cell lines. In addition, we found the SOX4 expression has a negative correlation with BG981369 expression, and the tumor-suppression effects of BG981369 may be produced through upregulating SOX4 expression.
Material and Methods

Cell lines and tissues
The human gastric cancer cell lines SNU-5, HGC-27, BGC-823, SGC-7901, and AGS, and the non-malignant gastric epithelial cell line GES-1 were all purchased from the American Type Culture Collection (ATCC). All cells were routinely cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin (Biochrom), and 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA) in an atmosphere of 5% CO 2 and 95% O 2 at 37°C. Gastric cancer tissues (n=44) and corresponding normal tissues (n=44) were obtained from GC patients at the First Affiliated Hospital of Wenzhou Medical University. Informed consent was provided by every GC patient, and ethics approval was obtained from the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. All tissues were frozen immediately in liquid nitrogen after surgical removal and maintained at -80°C until used.
lncRNA BG981369 overexpression and knockdown experiments
In the overexpression experiment, the cDNA of BG981369 was amplified by primers with 5'BamHI and 3'NotI restriction sites. PCR products were then digested with the 2-restriction endonuclease BamHI and NotI, and subcloned into the pcDNA 3.1 vector. To establish the BG981369 overexpression model, the plasmid was transfected into AGS cells using lipofectamine 2000 (Invitrogen, CA) following the protocol of the manufacturer. In the knockdown experiment, the siRNA targeting human lncRNA BG981369 (si-BG981369) and the negative control (NC) were obtained from Thermo Scientific (Ottawa, ON, Canada). SNU-5 cells were transfected with 20 nmol/L of si-BG981369 or control RNA using lipofectamine 2000 (Invitrogen).
RNA extraction, reverse transcription, and quantitative real-time PCR (qRT-PCR)
Total RNA of tissues or cell lines was extracted by TRIzol reagent (Invitrogen, Carlsbad, CA) and reverse transcription of total RNA was performed using SuperScript III Reverse Transcriptase (Invitrogen) following the instructions of the manufacturer. Quantitative real-time PCR was achieved by using the SYBR-Green PCR Master Mix kit (Takara) in PCR reaction and 7900 HT Fast (Applied Biosystems, CA). The reaction system of qRT-PCR is shown in Table 1 . Reaction steps were 95°C for 30 s as the first step in a loop, and 95°C for 5 s and 60°C for 34 s as the second step, for a total of 40 cycles. The sequence of primers used is shown in Table 2 . Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. The data were analyzed using 2 -DDCt calculation [18] .
Cell migration and invasion assay
Transwell chambers (8-μm pore size; BD Biosciences, San Jose, CA), with or without Matrigel coating, were used to detect the invasion or migration ability in treated GC cell lines, respectively. AGS cells with overexpressed BG981369or SNU-5 cells with blocked BG981369 were seeded in serum-free medium in the upper chamber at a concentration of 2×10 5 cells/ml (migration) or 1×10 5 cells/ml (invasion), and 600 μl medium containing 15% FBS was added into the lower chamber. After incubation at 37°C for 24 h (migration) or 48 h (invasion), cells remaining on the top layers of the inserts were removed, and the cells on the bottom were fixed and stained with 5% Crystal Violet (Cat # C-3886, Sigma-Aldrich, St. Louis, MO). The cells on the lower surface were counted in at least 6 random fields, and the average number was calculated.
Colony formation
Two groups of treated cells (AGS cells transfected with BG981369 or control, and SNU-5 cells transfected with si-BG981369 or si-NC) were collected and plated in 6-well plates at a concentration of 1×10 3 cells/well and cultured at 37°C in a 5% humidified CO 2 atmosphere for 2 weeks. After washing with PBS twice, cells were fixed with 10% formaldehyde and stained with 0.5% crystal violet at room temperature for 15 min. Visible colonies were counted manually.
Cell viability assay (MTT assay)
AGS cells transfected with BG981369 or control, and SNU-5 cells transfected with si-BG981369 or si-NC, were seeded into a 96-well plate at a density of 2×10 3 cells/well and maintained at 37°C for 24 h. Then, cells were washed 3 times in cold PBS, and 20 µl of MTT solution was added to each well. After incubation with MTT solution (Cat No: M-2128, Sigma, USA) for 30 min at 37°C, 150 µl dimethylsulfoxide (DMSO, Wako, cat. no. 045-24511) was added, and shaken at room temperature for 10 min. The absorbance of each well was determined by a use of a microplate reader at 490 nm.
Cell cycle analysis and apoptosis analysis
The cell cycle distribution of treated AGS and SNU-5 cells was analyzed by flow cytometry. Treated AGS or SNU-5 cells (1×10 6 cell/well) were seeded into 6-well plates and incubated overnight at 37°C. Cells were collected and fixed in 80% ethanol and maintained overnight at -20°C. Then, cells were washed at least 3 times in cold phosphate-buffered saline (PBS), and 500 μl PI/RNase buffer (BD bioscience, USA) was added for staining at room temperature (30 min in the dark). Cell cycle distribution was determined by use of a FACS-Calibur flow cytometer (Becton Dickinson, USA). For apoptosis analysis, treated AGS and SNU-5 cells were seeded into 6-well plates at a density of 1×10 6 cell/well and incubated overnight. After washing 3 times with PBS, cells were re-suspended with 0.5 mL binding buffer containing 5 µl phosphatidylethanolamine (PE) and Annexin-V-FITC for 10 min in the dark. Then, flow cytometry was used to analyze the apoptosis rate.
Statistical analysis
All statistical analyses were performed using SPSS 20.0 software (SPSS, Inc., Chicago, IL), and the t test and one-way ANOVA were used, as appropriate. All data are presented as mean ± standard deviation (SD), and P<0.05 was considered to indicate a statistically significant result. Previously research has analyzed the expression profiles of lncRNAs in human GC tissues relative to normal tissues, and found that expression of more than 100 lncRNAs was altered [19] . To investigate the exact roles of lncRNAs in human GC, we further detected the expression level of 6 different lncRNAs: AI769947, AK054978, DB077273, BG981369, AK054588, and AF131784.
Results from qRT-PCR showed that AI769947 expression was higher in the GC tissues than in normal tissues ( Figure 1A) , and BG981369 expression was significantly lower in the GC tissues than in corresponding normal tissues ( Figure 1D ). There was no obvious change in the expression levels of AK054978, DB077273, AK054588, and AF131784 in the human GC tissues relative to normal tissues ( Figure 1B , 1C, 1E, 1F). There results show that AI769947 and BG981369 may play a role in the progression and development of human GC.
lncRNA BG981369 inhibited cell proliferation and altered cell cycle in GC cell lines
To explore the biological functions of BG981369, we first measured the BG981369 expression in human GC cell lines These results suggested that BG981369 acts as a cell proliferation inhibitor in GC cell lines.
lncRNA BG981369 promoted cell apoptosis and inhibited cell migration and invasion in GC cell lines
We used Annexin V-FITC/PE double-staining and flow cytometry to measure the effects of BG981369 on cell apoptosis in GC cell lines. Results suggest that cell apoptosis was significantly higher in AGS cells transfected with BG981369 than in those transfected with control RNA, and the cell apoptosis rate was obviously lower in SNU-5 cells treated with si-BG981369 than in cells treated with si-NC ( Figure 3A) . Transwell assay was used to determine the effects of BG981369 on cell migration and invasion in GC cell lines. Results showed that the migration and invasion abilities were significantly decreased in the BG981369-overexpressed AGS cells, and were significantly increased in the BG981369-blocked SNU-5 cells ( Figure 3B, 3C ).
These results indicate that BG981369 induces cell apoptosis and inhibits cell migration and invasion in GC cell lines.
lncRNA BG981369 inhibited cell proliferation, migration, and invasion in a SOX4-dependent manner
Numerous of studies have demonstrated that the aberrant expression of SOX4 is involved in progression of various cancers [20] [21] [22] [23] . To investigate whether SOX4 plays a role in the effects of BG981369 on cell proliferation, migration, and invasion of GC cells, we further analyzed the SOX4 expression in GC tissues. Results from qRT-PCR showed that the relative SOX4 expression was significantly upregulated in GC tissues compared to normal tissues, and SOX4 expression was negatively correlated with BG981369 expression (Figure 4A, 4B ). Furthermore, the expression level of SOX4 was significantly decreased in the BG981369-overexpressed AGS cells, and was obviously increased in the BG981369 knockdown SNU-5 cells ( Figure 4C ). MTT assay results indicated that BG981369 overexpression inhibited the proliferation of AGS cells, BG981369 knockdown promoted proliferation of SNU-5 cells, and SOX4 blocked these effects of BG981369 on GC cell lines ( Figure 4D ). In addition, the inhibiting effects of BG981369 overexpression in AGS cells, and the promoting effects of BG981369 in SNU-5 cells were also blocked by the application of SOX4 ( Figure 4E ), suggesting that BG981369 is an inhibitor of cell proliferation, migration, and invasion via the SOX4 signaling pathway.
Discussion
Although the incidence of human gastric cancer has clearly dropped in recent decades, it remains the fourth most common type of cancer, and the 5-year survival rate of GC patients remains only around 30% [24, 25] . Since many factors are associated with the progression of GC, clinical treatment of this disease is extremely difficult and the mortality rate is relatively higher [26, 27] . Currently, the treatments of GC are mainly surgical removal combined with radiotherapy and chemotherapy; however, the effects of these treatments on GC are disappointing, especially in advanced or metastatic GC [28] . Defining the underlying mechanisms of GC will contribute to discovery of effective new therapeutic targets.
Emerging studies have identified numerous genes involved in the pathogenesis of human GC, and among these, lncRNAs are important [29, 30] . Emerging evidence demonstrated that lncRNAs participate in the biological processes of various cancer cells, including cell proliferation, development, apoptosis, and metastases [31, 32] .
A previous study revealed the expression profiles of lncRNAs in human GC tissues, and expression of a total of 135 lncRNAs was found to be altered more than 2-fold in GC tissues compared to normal tissues [19] . Among them, the expression levels of FER1L4, uc001lsz, BG491697, AF131784, AF131784, AK054588, AF147447, HMlincRNA1600, and BG981369 were the most reduced, and the expression levels of H19, HMlincRNA717, AI769947, BQ213083, AK054978, and DB077273 were the most increased [19] . In our study, we first measured the expression of 6 lncRNAs -AI769947, AK054978, DB077273, BG981369, AK054588, and AF131784 -by qRT-PCR, and results indicated that AI769947 expression was significantly higher, whereas BG981369 expression was significantly lower in GC tissues than in corresponding normal tissues. The 4 other lncRNAs showed no significant variation between GC tissues and normal tissues. To investigate the biological roles of BG981369 in human GC, we established a BG981369-overexpressed cell model by transfecting AGS cells with reconstructed plasmid containing BG981369, and we also established a BG981369-silenced cell model by treating SNU-5 cells with si-BG981369. After verifying the efficiency with qRT-PCR, these 2 cell models were used to explore the effects of BG981369 on cell proliferation, cell cycle distribution, apoptosis, migration, and invasion. Results from MTT analysis and colony formation assay showed that BG981369 overexpression inhibited cell proliferation, migration, and invasion, and promoted cell apoptosis, whereas BG981369 knockdown promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis. These results suggest that BG981369 is a tumor suppresser in the progression of GC.
SRY-related high-mobility group box 4 (SOX4), characterized by a highly conserved high-mobility group box domain, is an important transcription factor [33, 34] . Studies have demonstrated that SOX4 is involved in numerous biological processes, including central nervous system development and differentiation [35] [36] [37] . In addition, increasing evidence shows that SOX4 is involved in the progression of various cancers, such as lung cancer, endometrial cancer, and breast cancer [38] [39] [40] . However, whether SOX4 participates in the progression of GC remains unclear.
To explore whether SOX4 participates in the pathogenesis of human GC, we first measured the SOX4 expression by qRT-PCR, and found that SOX4 expression was significantly increased in the GC tissues compared to normal tissues. Furthermore, the expression level of SOX4 showed a negative correlation with BG981369 expression in GC cell lines. In addition, MTT and Transwell assays results indicated that SOX4 blocked the effects of tumor inhibition of BG981369 overexpression, and silenced SOX4 reversed the effects of tumor promotion of BG981369 knockdown in GC cell lines. These results suggest that SOX4 acts as a downstream mediator of BG981369 in GC.
Conclusions
The present research demonstrates that lncRNA BG981369 could be an important tumor growth inhibitor by targeting SOX4 in GC cell lines, suggesting that BG981369 and SOX4 may be potential therapeutic targets for GC.
